←Back to Expert Scholars
Translational Medicine / 转化医学Pembrolizumab Clinical Development
Gursel Aktan
MD
🏢Merck Research Laboratories🌐USA
Vice President, Oncology Clinical Research
40
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Gursel Aktan leads portions of the pembrolizumab clinical research program at Merck. She has been involved in KEYNOTE studies across thoracic, head and neck, and gynecologic cancers and contributes to the evaluation of immunotherapy combinations.
Share:
🧪Research Fields 研究领域
KEYNOTE trials
immunotherapy safety
combination immunotherapy
thoracic oncology
global clinical trials
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Gursel Aktan 的研究动态
Follow Gursel Aktan's research updates
留下邮箱，当我们发布与 Gursel Aktan（Merck Research Laboratories）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment